Welcome to our dedicated page for Sigyn Therapeutics news (Ticker: SIGY), a resource for investors and traders seeking the latest updates and insights on Sigyn Therapeutics stock.
Sigyn Therapeutics, Inc. (SIGY) is a development-stage medical technology company whose news flow centers on its dialysis-like blood purification therapies and related corporate developments. Company announcements highlight progress on Sigyn Therapy, a novel blood purification technology aimed at pathogen-associated inflammatory disorders, as well as its oncology-focused platforms ImmunePrep, ChemoPrep, and ChemoPure.
News releases frequently cover clinical and regulatory milestones, such as plans for first-in-human feasibility studies of Sigyn Therapy in end-stage renal disease patients with endotoxemia and concurrent inflammation, drafting of an Investigational Device Exemption for submission to the U.S. Food and Drug Administration, and discussions of potential Breakthrough Device submissions. Investors can also find updates on annual and quarterly financial results, including the filing of Form 10-K and other SEC reports referenced in company communications.
Sigyn Therapeutics also issues news about capital markets and corporate actions, including its 1-for-40 reverse stock split and efforts to meet listing requirements for The Nasdaq Capital Market. Coverage includes participation in emerging growth and small-cap conferences, such as the Emerging Growth Conference and LD Micro Main Event, where management presents updates on the companys therapeutic pipeline and development plans.
In addition, third-party research coverage, such as reports from Goldman Small Cap Research, is sometimes summarized in press releases that describe Sigyn Therapeutics as a developer of next-generation blood purification therapies for life-threatening conditions without FDA-approved treatments. For investors and observers, the SIGY news feed offers a consolidated view of clinical planning, technology development, financing steps, and investor outreach activities related to the companys blood purification and oncology-support platforms.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Sigyn Therapeutics announces the appointment of Annette Marleau, Ph.D. as Chief Scientific Officer, effective immediately. Dr. Marleau, an expert in blood purification technologies, previously served as Chief Technology Officer at Immunicom, leading R&D for cancer treatment candidates. She has significant achievements, including over $6 million in NIH funding and contributions to FDA-cleared Investigational Device Exemptions. Sigyn's lead product, Sigyn Therapy, is designed for pathogen-associated inflammatory disorders, targeting conditions like sepsis and pneumonia. The company's pipeline also includes ChemoPrep and ChemoPure, aimed at enhancing chemotherapy delivery and reducing toxicity. This leadership change could strengthen Sigyn's position in the competitive biotechnology market.
Sigyn Therapeutics, Inc. (OTCQB: SIGY) announced the filing of its Form 10-K annual report for the year ending December 31, 2022. The Company reported a net loss of approximately $2.9 million, consistent with the previous year's loss. In 2022, Sigyn advanced its Sigyn Therapy™ towards clinical studies, targeting pathogen-associated inflammatory disorders like sepsis and renal disease, and expanded its intellectual property and corporate team. Additionally, a cancer treatment system to enhance chemotherapy delivery was initiated. The Company utilized approximately $1.8 million in net cash for operating activities during the year.
Sigyn Therapeutics (OTCQB: SIGY) reported its third quarter results for 2022, showing a net loss of approximately $727,000 ($0.02 per share), slightly higher than the prior year's loss of $666,000. The company has advanced its operations by commencing trading on the OTCQB Venture Exchange and strengthening its Board of Directors. It is also pursuing first-in-human studies for Sigyn Therapy in End-Stage Renal Disease patients. Key developments include a provisional patent application for a cancer treatment system designed to enhance chemotherapy delivery and reduce toxicity.